芳香化酶抑制剂诱导的腕管综合征与狭窄性腱鞘炎:一项系统综述
该系统综述检索PubMed/MEDLINE、Ovid Embase和Cochrane Central Register of Controlled Trials(至2020年3月19日),并补充Google Scholar等来源,最终纳入19项研究,总结芳香化酶抑制剂诱导的腕管综合征与狭窄性腱鞘炎的危险因素、发生率及管理。危险因素包括试验前激素替代治疗、肌肉骨骼症状史、年龄小于60岁、既往化疗和体重指数大于25 kg/m2;发生率相比他莫昔芬可增高至10倍;非手术治疗可使高达67%的腕管综合征症状完全缓解;多数狭窄性腱鞘炎原始研究质量低,但均推荐手术松解以缓解症状。
要点
- 危险因素包括试验前激素替代治疗、肌肉骨骼症状史、年龄小于60岁、既往化疗和体重指数大于25 kg/m2。
- 芳香化酶抑制剂诱导的腕管综合征或狭窄性腱鞘炎发生率相比他莫昔芬可增高至10倍。
- 非手术治疗可使高达67%的腕管综合征症状完全缓解;多数狭窄性腱鞘炎原始研究质量低,但均推荐手术松解。
核心结论
- 本综述总结了芳香化酶抑制剂诱导的腕管综合征与狭窄性腱鞘炎的相关危险因素、管理选项和文献质量。
- 早期识别可防止患者自行停用芳香化酶抑制剂以及腕管综合征和狭窄性腱鞘炎治疗不当的长期后遗症。
研究设计与样本
- 遵循PRISMA指南的系统综述,检索PubMed/MEDLINE、Ovid Embase和Cochrane Central Register of Controlled Trials(至2020年3月19日),并补充Google Scholar、Plastic and Reconstructive Surgery和The Journal of Hand Surgery。
- 两位评审员独立完成初筛和二次筛选以及质量评价,共审阅577篇摘要,纳入19项研究。
主要发现
- 危险因素包括试验前激素替代治疗、肌肉骨骼症状史、年龄小于60岁、既往化疗和体重指数大于25 kg/m2。
- 芳香化酶抑制剂诱导的腕管综合征或狭窄性腱鞘炎发生率相比他莫昔芬可增高至10倍。
- 有报告患者因腕管综合征和狭窄性腱鞘炎而停用芳香化酶抑制剂治疗。
- 非手术治疗可使高达67%的腕管综合征症状完全缓解。
- 多数芳香化酶抑制剂诱导的狭窄性腱鞘炎原始研究质量低,但所有研究均推荐手术松解以缓解症状。
临床怎么用
- 早期识别可防止患者自行停用芳香化酶抑制剂以及腕管综合征和狭窄性腱鞘炎治疗不当的长期后遗症。
局限性
- 多数芳香化酶抑制剂诱导的狭窄性腱鞘炎原始研究质量低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although aromatase inhibitors are the first-line treatment in postmenopausal women with hormone receptor-positive breast cancer, there is increasing evidence that they can induce carpal tunnel syndrome and stenosing tenosynovitis. This systematic review summarizes the risk factors, incidence, and management for patients with aromatase inhibitor-induced carpal tunnel syndrome and stenosing tenosynovitis compared to tamoxifen or placebo. METHODS: A Preferred Reporting Items for Systematic Reviews and Meta-Analyses-guided systematic review of PubMed/MEDLINE, Ovid Embase, and the Cochrane Central Register of Controlled Trials was conducted (to March 19, 2020), supplemented with Google Scholar, Plastic and Reconstructive Surgery, and The Journal of Hand Surgery. Two reviewers independently completed the primary and secondary screens and the quality appraisal. RESULTS: This study reviewed 577 abstracts and included 19 studies. Risk factors for aromatase inhibitor-induced carpal tunnel syndrome or stenosing tenosynovitis included hormone replacement therapy before trial entry, history of musculoskeletal symptoms, age younger than 60 years, prior chemotherapy, and body mass index greater than 25 kg/m2. The incidence can be increased up to 10 times compared to tamoxifen. Patient discontinuation of aromatase inhibitor treatment because of carpal tunnel syndrome and stenosing tenosynovitis was reported. Nonsurgical management led to complete resolution of carpal tunnel syndrome symptoms in up to 67 percent of cases. Although most aromatase inhibitor-induced stenosing tenosynovitis original studies were low quality, all recommended surgical release for symptom resolution. CONCLUSIONS: This study provides current knowledge of the associated risk factors, management options, and quality of literature for aromatase inhibitor-induced carpal tunnel syndrome and stenosing tenosynovitis. Early recognition can prevent self-discontinuation of an aromatase inhibitor and long-term sequelae of poorly treated carpal tunnel syndrome and stenosing tenosynovitis.
引用
- Chung KY, Ho G, Novak CB, et al. Aromatase Inhibitor-Induced Carpal Tunnel Syndrome and Stenosing Tenosynovitis: A Systematic Review. Plast Reconstr Surg. 2022. PMID: 35196681. doi:10.1097/PRS.0000000000008835
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。